Rezubio Commences Landmark Phase I Trial for RZ-520, an Inhaled Therapy for Chronic Respiratory Diseases

Shanghai, China & San Diego, USA – [Current Date, e.g., October 26, 2026] – Rezubio, a pioneering biopharmaceutical company at the forefront of innovative drug design, has announced a significant milestone in its pipeline development: the successful dosing of the first cohort of healthy volunteers in a Phase I clinical trial for RZ-520. This novel inhaled therapeutic drug is specifically engineered to address the substantial unmet medical needs of patients suffering from chronic respiratory diseases. The initiation of this crucial study follows the receipt of Investigational New Drug (IND) clearances from two of the world’s most stringent regulatory bodies: the US Food and Drug Administration (FDA) and China’s National Medical Products Administration (NMPA).

n

RZ-520 represents the second clinical candidate to emerge from Rezubio’s proprietary Membrane-Anchored Drug Design (MADD) platform. This platform is a testament to Rezubio’s commitment to developing tissue-targeted treatments that are designed to remain locally active for extended periods, thereby maximizing therapeutic effect while minimizing systemic exposure and potential side effects. The Phase I trial is meticulously designed to assess the tolerability, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of RZ-520 in healthy individuals, laying the foundational groundwork for its potential future development as a transformative treatment option.

n

Main Facts: A New Era for Respiratory Therapies

n

Rezubio’s RZ-520 is not just another drug; it embodies a paradigm shift in how chronic respiratory diseases might be managed. By leveraging its innovative MADD platform, Rezubio aims to deliver a therapeutic agent directly to the pulmonary tissues, where it is needed most, and ensure its sustained presence without widespread distribution throughout the body. This targeted approach promises enhanced efficacy, a more favorable safety profile, and increased convenience for patients, potentially alleviating the burden associated with current treatment regimens.

n

The simultaneous IND clearances from both the FDA and NMPA underscore the robust preclinical data supporting RZ-520 and highlight the global potential of this therapeutic candidate. It also reflects Rezubio’s strategic vision to develop drugs with broad international applicability, addressing global health challenges. For patients grappling with debilitating conditions such as asthma, chronic obstructive pulmonary disease (COPD), and other chronic lung ailments, RZ-520 offers a beacon of hope for more effective and safer long-term management. The commencement of this Phase I trial is a critical step in translating this scientific innovation into tangible patient benefits.

n

Chronology: From Concept to Clinical Reality

n

The journey of RZ-520 from a theoretical concept to a clinical-stage asset is a testament to years of dedicated research, meticulous development, and strategic planning.

n

Early Genesis of the MADD Platform:nThe MADD platform likely began years ago, perhaps in the late 2010s or early 2020s, with a fundamental scientific inquiry: how can drugs be designed to localize their action to specific tissues, prolong their therapeutic effect, and minimize systemic exposure? This foundational research would have involved deep dives into cell membrane biology, protein-drug interactions, and novel chemical conjugation techniques. The core idea would have been to anchor therapeutic molecules to the surface of target cells or within the extracellular matrix of specific tissues, effectively creating a "depot" of active drug. This approach directly addresses a major challenge in drug delivery – achieving high local concentrations without the systemic toxicity often associated with high-dose systemic administration. The initial conceptualization and proof-of-concept studies, likely conducted in vitro and in early animal models, would have laid the groundwork for its broad applicability.

n

Preclinical Research and Development of RZ-520:nFollowing the successful establishment of the MADD platform’s principles, Rezubio embarked on applying it to specific disease areas. Chronic respiratory diseases, with their localized pathology and the potential for inhaled delivery, presented an ideal target. The development of RZ-520 would have involved a rigorous process of drug candidate selection, chemical optimization, and extensive preclinical testing. This phase would have included:

n

n
• Target Identification and Validation: Identifying specific molecular targets within the lung tissue relevant to chronic respiratory inflammation and remodeling.

n

• Lead Compound Synthesis and Optimization: Designing and synthesizing numerous MADD-modified drug candidates, evaluating their stability, anchoring efficiency, and target binding affinity.

n

• In Vitro Studies: Conducting cell-based assays to assess the drug’s activity, cell viability, and sustained release properties in lung epithelial cells, immune cells, and fibroblasts.

n

• In Vivo Animal Models: Testing RZ-520 in various animal models of chronic respiratory diseases, such as allergen-induced asthma models, smoke-induced COPD models, or models of pulmonary fibrosis. These studies would have evaluated the drug’s ability to reduce inflammation, improve lung function, and prevent tissue damage. Crucially, these studies would also have provided the initial evidence for limited systemic exposure, a key advantage of the MADD platform.

n

• Toxicology and Safety Studies: Comprehensive toxicology studies in multiple animal species to identify any potential adverse effects, determine a safe dose range, and support the drug’s safety for human trials. These studies are critical for regulatory submissions.

n

n

The IND Submission Process: A Dual Regulatory Triumph:nThe submission of an Investigational New Drug (IND) application is a monumental undertaking, requiring vast amounts of data from preclinical studies, manufacturing processes, and proposed clinical protocols. For RZ-520, Rezubio pursued dual IND clearances from both the US FDA and China’s NMPA. This simultaneous pursuit reflects a strategic desire to accelerate global development and potentially reach a broader patient population more quickly.

n

n
• FDA IND Clearance: The FDA’s review process is renowned for its rigor, focusing on the scientific soundness of the preclinical data, the safety profile of the drug, and the ethical considerations of the proposed clinical trial. Receiving FDA clearance is a strong validation of RZ-520’s potential and safety for human testing.

n

• NMPA IND Clearance: China’s NMPA has also significantly strengthened its regulatory review processes in recent years, aligning more closely with international standards. Gaining NMPA approval concurrently with the FDA demonstrates the high quality of Rezubio’s data package and its ability to navigate complex global regulatory landscapes.nThese dual clearances are not merely administrative approvals; they are scientific endorsements from leading global health authorities, signaling confidence in RZ-520’s readiness for human investigation.

n

n

First Cohort Dosing: A Momentous Step:nThe dosing of the first cohort of healthy volunteers marks the official transition of RZ-520 from preclinical research into human clinical development. This event is meticulously planned and executed, with the primary objective of the Phase I trial being to establish the drug’s safety and tolerability in humans. Participants are closely monitored for any adverse events, and biological samples are collected to analyze the drug’s pharmacokinetics and pharmacodynamics. This step is a critical inflection point, moving from theoretical potential to real-world assessment.

n

Funding Milestones: Fueling Innovation:nWhile the current Phase I trial is for RZ-520, Rezubio’s broader financial health and investor confidence are crucial for the continued advancement of its pipeline. In December 2025, Rezubio successfully secured $20 million in a Series A financing round. This significant investment, led by Lapam Capital with participation from Riverhead Capital and Frees Fund, was specifically earmarked to advance Rezubio’s lead program – likely another MADD-derived candidate targeting diabetes and obesity – into Phase II clinical development. This funding round, occurring just prior to the RZ-520 announcement, signifies strong investor belief in the MADD platform’s potential across various therapeutic areas, providing the financial stability necessary to pursue multiple innovative programs simultaneously. The ability to attract such substantial investment underscores the perceived value and potential of Rezubio’s technology.

n

Supporting Data: The Science Behind the Promise

The scientific foundation of RZ-520 and the MADD platform is what truly differentiates Rezubio in the competitive biopharmaceutical landscape.

The Science Behind RZ-520 and the MADD Platform:
The Membrane-Anchored Drug Design (MADD) platform is a sophisticated biotechnological approach that engineers therapeutic molecules to specifically bind and anchor to cell surface proteins or components of the extracellular matrix within a target tissue. This anchoring mechanism serves several critical functions:

• Localized Drug Exposure: By tethering the drug to the desired tissue, MADD ensures a high local concentration of the therapeutic agent precisely where it is needed. For RZ-520, this means maintaining drug exposure within the lung tissue.
• Restricted Systemic Distribution: The anchoring prevents the drug from rapidly diffusing into the bloodstream and distributing throughout the body. This significantly reduces the potential for systemic side effects, a common challenge with many traditional drug therapies.
• Prolonged Therapeutic Effect: By keeping the drug localized, its residence time at the target site is extended, potentially allowing for less frequent dosing and improved patient compliance.
• Enhanced Efficacy: A sustained high concentration at the site of action can lead to a more potent and consistent therapeutic effect, potentially overcoming limitations of drugs that are rapidly cleared from the target tissue.

For RZ-520, this means designing a molecule that can be inhaled and then efficiently and durably anchor itself within the complex microenvironment of the lung. This sophisticated design aims to maximize the drug’s impact on chronic respiratory diseases, which are often characterized by persistent inflammation, airway remodeling, and impaired lung function.

Pharmacokinetics (PK) and Pharmacodynamics (PD) in Inhaled Therapies:
The Phase I trial is rigorously assessing PK and PD, which are fundamental to understanding how RZ-520 behaves in the human body.

• Pharmacokinetics (PK): This branch of pharmacology describes the fate of a drug in the body, encompassing its absorption, distribution, metabolism, and excretion (ADME). For an inhaled drug like RZ-520, key PK parameters will include:
  • Lung Deposition and Absorption: How much of the inhaled dose reaches the lungs, and how efficiently is it absorbed into the lung tissue?
  • Local Distribution and Retention: How long does the drug remain anchored within the lung, and what is its concentration profile over time?
  • Systemic Exposure: Critically, what is the extent of drug absorption into the systemic circulation? The MADD platform’s goal is to minimize this.
  • Metabolism and Excretion: How is any systemically absorbed drug processed and eliminated from the body?
• Pharmacodynamics (PD): This describes the drug’s effect on the body. While Phase I in healthy volunteers primarily focuses on safety, early PD markers might be explored to understand the drug’s biological activity. For RZ-520, future PD studies in patients would look at markers of inflammation, airway hyperresponsiveness, or lung function improvements. The current Phase I trial will focus on measuring early physiological responses and potential biomarker changes in healthy volunteers that could indicate the drug’s intended mechanism of action.

Safety and Tolerability:
In Phase I trials, safety and tolerability are paramount. Researchers are looking for any adverse events (AEs) or side effects that occur in response to the drug. For an inhaled drug, particular attention is paid to:

• Local Respiratory Effects: Cough, bronchospasm, throat irritation, or other lung-related symptoms.
• Systemic Effects: Any adverse events in other organ systems that might indicate systemic drug exposure.
• Dose-Response Relationship: Identifying the maximum tolerated dose (MTD) and understanding how safety changes with increasing drug concentrations.
  The careful monitoring of these parameters in healthy volunteers ensures that the drug is safe enough to proceed to studies in patient populations.

Chronic Respiratory Diseases Landscape:
Chronic respiratory diseases represent a significant global health burden, affecting hundreds of millions of people worldwide. Conditions like asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and idiopathic pulmonary fibrosis lead to progressive lung damage, impaired quality of life, and substantial healthcare costs. Current treatments often involve inhaled corticosteroids, bronchodilators, and other anti-inflammatory agents. While effective for many, these treatments often have limitations:

• Systemic Side Effects: High doses of inhaled corticosteroids, for example, can still lead to systemic side effects like osteoporosis or adrenal suppression.
• Compliance Issues: Daily adherence to inhaled regimens can be challenging for patients.
• Limited Efficacy: Some patients respond poorly to existing therapies, experiencing persistent symptoms and frequent exacerbations.
• Disease Progression: Many current therapies manage symptoms but do not halt or reverse disease progression.
  RZ-520, with its tissue-targeted and sustained-release design, aims to overcome these limitations by offering a treatment that is more potent, safer, and potentially more convenient, ultimately improving patient outcomes and potentially altering the natural course of these debilitating diseases.

Preclinical Findings – A Deeper Dive:
Rezubio’s preclinical work for RZ-520 was instrumental in securing the dual IND clearances. The findings indicated significant therapeutic activity across several disease models, meaning the drug was able to alleviate disease symptoms or pathology in laboratory settings. These models might have included:

• Allergen-Induced Airway Inflammation: Demonstrating reduced inflammatory cell infiltration, cytokine production, and airway hyperresponsiveness.
• Chronic Exposure Models: Showing improvement in lung function, reduction in emphysema-like changes, or attenuation of fibrosis in models mimicking long-term exposure to irritants.
  Crucially, these studies also revealed limited systemic exposure, confirming the MADD platform’s ability to localize the drug. While these early-stage findings have not yet been confirmed in humans, they provide a strong scientific rationale for proceeding with clinical trials. They are the essential bridge between theoretical science and practical medicine, indicating a high probability of clinical benefit.

Official Responses: Leadership’s Vision and Validation

The announcement was met with enthusiastic commentary from Rezubio’s leadership, articulating the strategic importance of this milestone.

Rezubio CEO Yusheng Xiong’s Statement:
Rezubio CEO Yusheng Xiong underscored the profound significance of the dual IND clearances and the initiation of the Phase I trial for RZ-520. "The dual IND clearances from the FDA and NMPA and first cohort dosing of RZ-520 mark a pivotal milestone for both this program and our MADD platform," Xiong stated. This declaration highlights several key aspects:

• Pivotal Milestone: This is not merely an incremental step but a defining moment that validates years of research and development. It signifies the transition from preclinical promise to human clinical evaluation, a critical hurdle for any drug candidate.
• Validation of the MADD Platform: The successful advancement of RZ-520, following another MADD-derived candidate, serves as powerful validation of the platform’s versatility and efficacy in generating viable drug candidates. It demonstrates that the MADD concept is not limited to a single therapeutic area but has broad applicability, reinforcing investor confidence and potential for future pipeline expansion.
• Addressing Challenging Diseases: Xiong’s emphasis on the MADD platform’s power "to design tissue-targeted therapies that address a broad spectrum of challenging diseases" points to Rezubio’s ambitious vision. Chronic respiratory diseases are notoriously complex and difficult to manage, and a platform that can deliver targeted, sustained action offers a novel approach to tackling these challenges.
• Transformative Potential: The CEO expressed optimism for RZ-520’s potential to deliver a "transformative, highly differentiated treatment option for patients living with chronic respiratory diseases." This speaks to the aspiration of not just improving existing treatments but fundamentally changing the treatment landscape, offering a superior therapeutic profile in terms of efficacy, safety, and patient convenience.

These statements from the leadership reflect not only the immediate success but also the broader strategic implications for Rezubio’s future as an innovative biopharmaceutical entity.

Implications: A Glimpse into the Future of Medicine

The progression of RZ-520 into clinical trials carries significant implications, not only for Rezubio but for the broader field of respiratory medicine and drug development.

Impact on Chronic Respiratory Disease Treatment:
If RZ-520 successfully navigates the rigorous phases of clinical development, its impact on chronic respiratory disease treatment could be profound.

• Improved Patient Outcomes: By maintaining drug exposure within the lung while restricting systemic distribution, RZ-520 could offer superior efficacy in reducing inflammation, improving lung function, and preventing exacerbations, with a significantly reduced risk of systemic side effects. This could lead to better disease control and an enhanced quality of life for millions of patients.
• Enhanced Safety Profile: The localized action of RZ-520 is designed to mitigate common systemic adverse effects associated with existing therapies, such as bone density loss, increased infection risk, or cardiovascular issues. This improved safety profile would be a significant advantage, particularly for long-term treatment.
• Dosing Convenience and Adherence: A prolonged local action could potentially lead to less frequent dosing, simplifying treatment regimens and improving patient adherence, which is a major challenge in chronic disease management.
• New Therapeutic Avenues: RZ-520 could potentially be effective in patient populations who are refractory to current treatments, or for diseases where systemic side effects limit the use of otherwise potent drugs. It could also enable the use of drugs that were previously deemed too toxic for systemic administration, but which could be highly effective if localized.

Future of the MADD Platform:
The success of RZ-520 would be a resounding endorsement of the MADD platform’s potential, opening doors for its application across a multitude of other localized diseases.

• Pipeline Expansion: Rezubio has already demonstrated the platform’s versatility with a lead candidate for diabetes and obesity. Future applications could extend to other gastrointestinal conditions (e.g., inflammatory bowel disease), dermatological disorders, ocular diseases, or even certain localized cancers where targeted delivery could enhance efficacy and reduce systemic toxicity.
• Partnerships and Licensing: A validated platform with successful clinical assets would make Rezubio an attractive partner for larger pharmaceutical companies seeking innovative drug delivery technologies. This could lead to licensing agreements, co-development opportunities, and significant revenue streams.
• Broader Impact on Drug Design: The MADD platform could inspire further innovation in the field of targeted drug delivery, pushing the boundaries of how drugs are designed and administered to maximize therapeutic benefits while minimizing risks.

Rezubio’s Position in the Biopharmaceutical Landscape:
This clinical advancement solidifies Rezubio’s position as an emerging leader in innovative biopharmaceutical research.

• Increased Investor Confidence: The dual IND clearances and progression to Phase I are strong signals to investors, potentially attracting further funding rounds necessary for later-stage clinical trials. This confidence is critical for a biotech company in the capital-intensive drug development industry.
• Competitive Edge: In a crowded therapeutic landscape, a truly novel platform like MADD provides a significant competitive advantage. Rezubio is not just developing new drugs, but a new way of developing drugs, which could lead to a differentiated and valuable pipeline.
• Talent Attraction: Success in clinical development enhances a company’s reputation, making it more attractive to top scientific and clinical talent, further fueling its innovation engine.

Challenges and Next Steps:
Despite the optimism, the road ahead for RZ-520 is long and fraught with inherent challenges typical of drug development.

• Clinical Trial Hurdles: Phase I is just the beginning. RZ-520 must successfully navigate Phase II trials (evaluating efficacy and optimal dosing in patient populations) and Phase III trials (large-scale confirmatory studies comparing it to existing treatments). Each phase carries a high risk of failure.
• Regulatory Approval: Even after successful clinical trials, obtaining final regulatory approval from the FDA, NMPA, and other global agencies is a complex and lengthy process.
• Commercialization: If approved, Rezubio will face the challenges of manufacturing, marketing, and commercializing RZ-520 in a competitive market.

The immediate next steps for Rezubio will involve meticulously analyzing the data from the Phase I trial, particularly concerning safety, tolerability, PK, and early PD signals. Based on these results, the company will plan and initiate subsequent Phase II studies, moving closer to its ultimate goal of delivering a truly transformative treatment for chronic respiratory diseases. The journey of RZ-520 epitomizes the high-stakes, high-reward nature of modern pharmaceutical innovation, holding the promise of significant improvements in patient care worldwide.